NASDAQ:ONC BeOne Medicines (ONC) Stock Price, News & Analysis $289.75 +1.57 (+0.54%) As of 08/11/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About BeOne Medicines Stock (NASDAQ:ONC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BeOne Medicines alerts:Sign Up Key Stats Today's Range$286.57▼$290.0050-Day Range$240.99▼$307.2352-Week Range$170.99▼$313.29Volume394,876 shsAverage Volume465,192 shsMarket Capitalization$31.76 billionP/E RatioN/ADividend YieldN/APrice Target$330.89Consensus RatingBuy Company Overview BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland. Read More BeOne Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreONC MarketRank™: BeOne Medicines scored higher than 27% of companies evaluated by MarketBeat, and ranked 1632nd out of 1,853 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingBeOne Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBeOne Medicines has only been the subject of 4 research reports in the past 90 days.Read more about BeOne Medicines' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BeOne Medicines are expected to grow in the coming year, from ($5.82) to $0.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BeOne Medicines is -167.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BeOne Medicines is -167.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeOne Medicines has a P/B Ratio of 8.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ONC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBeOne Medicines does not currently pay a dividend.Dividend GrowthBeOne Medicines does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ONC. News and Social Media1.9 / 5News Sentiment0.47 News SentimentBeOne Medicines has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for BeOne Medicines this week, compared to 7 articles on an average week.Search InterestOnly 4 people have searched for ONC on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added BeOne Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BeOne Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,294,047.00 in company stock.Percentage Held by InsidersOnly 6.62% of the stock of BeOne Medicines is held by insiders.Percentage Held by Institutions48.55% of the stock of BeOne Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BeOne Medicines' insider trading history. Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BeOne Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address ONC Stock News HeadlinesBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Lai Wang Sells 259 SharesAugust 1, 2025 | insidertrades.comBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Lai Wang Sells 700 SharesJuly 23, 2025 | insidertrades.comAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.August 12 at 2:00 AM | Brownstone Research (Ad)BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) CEO John Oyler Sells 27,802 SharesJuly 12, 2025 | insidertrades.comBeOne Medicines (NASDAQ:ONC) Stock Rating Upgraded by Wall Street ZenAugust 11 at 3:33 AM | americanbankingnews.comBeOne Medicines Ltd. (NASDAQ:ONC) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | msn.comBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Receives $327.56 Average PT from AnalystsAugust 7, 2025 | americanbankingnews.comBeOne Medicines outlines $5B–$5.3B 2025 revenue target as BRUKINSA leads BTK market and global expansion acceleratesAugust 6, 2025 | msn.comSee More Headlines ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed this year? BeOne Medicines' stock was trading at $223.50 on January 1st, 2025. Since then, ONC stock has increased by 29.6% and is now trading at $289.75. How were BeOne Medicines' earnings last quarter? BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) issued its quarterly earnings data on Wednesday, August, 6th. The company reported $0.84 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.36. The business earned $1.32 billion during the quarter, compared to the consensus estimate of $1.24 billion. BeOne Medicines had a negative net margin of 3.89% and a negative trailing twelve-month return on equity of 1.22%. Who are BeOne Medicines' major shareholders? BeOne Medicines' top institutional investors include Primecap Management Co. CA (4.64%), Connor Clark & Lunn Investment Management Ltd. (0.28%), Candriam S.C.A. (0.26%) and Artisan Partners Limited Partnership (0.25%). Insiders that own company stock include Lai Wang, Lai Wang, Bros Advisors Lp Baker, Xiaodong Wang, Xiaobin Wu, Titus B Ball, Aaron Rosenberg, John Oyler and Chan Henry Lee. View institutional ownership trends. How do I buy shares of BeOne Medicines? Shares of ONC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/06/2025Today8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ONC Previous SymbolNASDAQ:ONC CIK1651308 WebN/A Phone13459494123FaxN/AEmployees11,000Year FoundedN/APrice Target and Rating Average Price Target for BeOne Medicines$330.89 High Price Target$365.00 Low Price Target$259.00 Potential Upside/Downside+14.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$644.79 million Net Margins-3.89% Pretax Margin-1.39% Return on Equity-1.22% Return on Assets-0.72% Debt Debt-to-Equity Ratio0.04 Current Ratio1.95 Quick Ratio1.72 Sales & Book Value Annual Sales$3.81 billion Price / Sales8.33 Cash FlowN/A Price / Cash FlowN/A Book Value$34.10 per share Price / Book8.50Miscellaneous Outstanding Shares109,600,000Free Float102,344,000Market Cap$31.76 billion OptionableN/A Beta0.27 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ONC) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredSilver Demand Is Exploding—and Supply Can’t Keep UpElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeOne Medicines Ltd. - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BeOne Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.